Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord mesenchymal stem cells for spinal cord injury repair
ChiCTR2200061962Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jun 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of human umbilical cord mesenchymal stem cells in spinal cord injury (SCI) and acute spinal cord injury (SCI) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: ASIA Spinal Cord Injury Score, IANR Spinal Cord Injury Function Assessment Scale and 5 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
spinal cord injury (SCI)acute spinal cord injury (SCI)
Beyond the preview
Go deeper on ChiCTR2200061962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061962.